Le Lézard
Classified in: Health
Subjects: TRI, PET

Pharos Diagnostics Expands Diagnostic Testing Menu to include Routine Testing and Valley Fever (Cocci)


TUCSON, Ariz., April 4, 2018 /PRNewswire/ -- Pharos Diagnostics recently expanded testing services to provide routine testing capabilities in chemistry, hematology and immunoassay as well as Valley Fever (Coccidioidomycosis) testing.  The broadened menu compliments the laboratory's existing esoteric mass spectrometry testing services allowing Pharos to better serve regional customers' diagnostic testing needs.  Pharos recently rolled out and completed a soft launch of these services and is actively processing samples for human and veterinary clinics and hospitals in the region.

Coccidioidomycosis (cocci) infection comes from inhalation of a soil-borne fungus which normally affects the respiratory system. However, it can spread throughout the body and is occasionally fatal. This fungus is typically found in the arid southwestern United States including southern California, Arizona, southwest Texas, New Mexico, Nevada, and Utah, as well as some South American countries. Cocci testing for the identification of the fungus is currently one of the most requested tests by veterinarians in the US southwest region. Humans and animals (particularly dogs) are susceptible to cocci infection and Pharos Diagnostics is uniquely positioned to support both veterinary and clinical practitioners in diagnosing cocci infections because of the laboratory's CLIA (Clinical Laboratory Improvement Amendments) certification.

Valley Fever illustrates the importance of One Health, the initiative converging human and veterinary medicine to improve health for people and animals. Pharos Diagnostics and Pharos Veterinary Diagnostics are uniquely positioned to identify best practices in One Health medicine to deliver best in class diagnostics across species to both doctors and veterinarians.

Pharos Diagnostics provides faster turnaround time, better accuracy, and lower costs to veterinary, clinical and academic customers.

As the leading commercial mass spectrometer laboratory in Southern Arizona, Pharos Diagnostics is proud to be a participant and supporter of the Tucson area's rapidly growing center of diagnostic excellence.

 About Pharos Diagnostics LLC.

Pharos Diagnostics LLC. is a privately-held corporation headquartered in Tucson, AZ primarily serving the western and southwestern regions of the United States and operates Pharos Veterinary Diagnostics to serve the veterinarian community. Pharos Diagnostics is CLIA-certified and meets all regulatory, fair billing practice and state and federal requirements. To learn more visit www.pharosdx.com, www.pharosvetdx.com or call 520-355-4500.

For more information, please contact Mike Bergthold at (602) 885-3795.

 

SOURCE Pharos Diagnostics


These press releases may also interest you

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...



News published on and distributed by: